Cargando…
Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent
LASSBio-1920 was synthesized due to the poor solubility of its natural precursor, combretastatin A4 (CA4). The cytotoxic potential of the compound against human colorectal cancer cells (HCT-116) and non-small cell lung cancer cells (PC-9) was evaluated, yielding IC(50) values of 0.06 and 0.07 μM, re...
Autores principales: | Guimarães, Celina de Jesus, Carneiro, Teiliane Rodrigues, Frederico, Marisa Jadna Silva, de Carvalho, Guilherme G. C., Little, Matthew, Freire, Valder N., França, Victor L. B., do Amaral, Daniel Nascimento, Guedes, Jéssica de Siqueira, Barreiro, Eliezer J., Lima, Lídia Moreira, Barros-Nepomuceno, Francisco W. A., Pessoa, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144566/ https://www.ncbi.nlm.nih.gov/pubmed/37111767 http://dx.doi.org/10.3390/pharmaceutics15041282 |
Ejemplares similares
-
Impairment of locomotor activity induced by the novel
N-acylhydrazone derivatives LASSBio-785 and LASSBio-786 in
mice
por: Silva, G.A.P., et al.
Publicado: (2013) -
Pre-clinical evaluation of LASSBio-1491: From in vitro pharmacokinetic study to in vivo leishmanicidal activity
por: de Queiroz, Aline Cavalcanti, et al.
Publicado: (2022) -
LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice
por: Silva, Juliane Cabral, et al.
Publicado: (2018) -
Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema
por: Padilha, Gisele A., et al.
Publicado: (2015) -
Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H(2)LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H(2)LASSBio-1064) and Their Zinc(II) Complexes
por: Júnior, Walfrido Bispo, et al.
Publicado: (2011)